News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
FDA Grants Breakthrough Therapy Status to Merck’s Calderasib for KRAS G12C-Mutated NSCLC
Saturday, May 30, 2026Merck known as MSD outside the United States and Canada has received Breakthrough Therapy designation from the US Food and Drug Administration FDA for calderasib MK an investigational oral KRAS GC inhibitor
Innovent Biologics and Pfizer form global partnership for oncology drug development
Friday, May 29, 2026Innovent Biologics and Pfizer have entered into a global strategic collaboration to develop earlystage and newly discovered cancer medicines The agreement covers the research and development of antibodydrug conjugates
Alzprotect receives FDA clearance for AZP2006 trial in PSP
Thursday, May 28, 2026Alzprotect has received clearance from the US Food and Drug Administration for its Investigational New Drug IND application for AZP Ezeprogind to treat Progressive Supranuclear Palsy PSP
CordenPharma to Acquire AmbioPharm to Expand Global Peptide API Capacity
Wednesday, May 27, 2026CordenPharma has announced an agreement to acquire AmbioPharm a USbased peptide active pharmaceutical ingredient API contract development and manufacturing organisation CDMO
Engage Bio Acquired by Lilly to Support Development of Non-Viral Genetic Medicines
Thursday, May 21, 2026Engage Biologics Inc a preclinical biotechnology company focused on nonviral DNA delivery has been acquired by Eli Lilly and Company
Hansa Biopharma signs €115 million IDEFIRIX licensing agreement with SERB Pharmaceuticals
Wednesday, May 20, 2026Hansa Biopharma has entered into an exclusive licensing agreement worth million with SERB Pharmaceuticals for the development and commercialisation of IDEFIRIX imlifidase across Europe and the Middle East and North Africa MENA region
Regeneron and Parabilis Medicines Partner to Develop Novel Antibody-Helicon Therapies
Tuesday, May 19, 2026Regeneron Pharmaceuticals has entered into a strategic research collaboration with Parabilis Medicines to develop multiple therapeutic candidates based on Parabilis Helicon peptide platform with a focus on AntibodyHelicon Conjugates AHCs
INmune Bio receives FDA Fast Track designation for XPro1595 in early Alzheimer’s disease
Friday, May 15, 2026INmune Bio Inc has announced that the US Food and Drug Administration has granted Fast Track designation to XPro pegipanermin for the treatment of early Alzheimers disease
U.S. FDA Approves INQOVI® Plus Venetoclax for Acute Myeloid Leukaemia
Thursday, May 14, 2026Taiho Oncology and Taiho Pharmaceutical have received approval from the US Food and Drug Administration for INQOVI decitabine and cedazuridine in combination with venetoclax for the treatment
4basebio launches enzymatic ssDNA platform for gene editing applications
Tuesday, May 12, 2026basebio PLC has launched a highcapacity singlestranded DNA ssDNA platform designed to support the development of gene editing and nucleic acidbased therapies
